Spyridon Papapetropoulos
Fortune : 145 533 $ au 31/08/2026
Fortune : 145 533 $ au 31/08/2026
Dr. Spyridon Papapetropoulos is a Chief Executive Officer & Executive Director at Neuphoria Therapeutics, Inc., a President, Chief Executive Officer & Director at Bionomics Ltd. and a President at Encephalos Life Sciences LLC.
He is on the Board of Directors at Neuphoria Therapeutics, Inc. and Bionomics Ltd. Dr. Papapetropoulos was previously employed as a Chairman by Lipocine, Inc., an Independent Director by Adamas Pharmaceuticals LLC, a Chief Medical Officer by Vigil Neuroscience, Inc., a Chief Development Officer, SVP & Head-Development by ACADIA Pharmaceuticals, Inc., a Chief Executive Officer by SwanBio Therapeutics, Inc., and a Chief Medical Officer & EVP-R&D by Cavion, Inc. He received his doctorate degree from the University of Patras and a doctorate degree from Semmelweis University.
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
0,32% | 16/04/2025 | 5 999 940 ( 0,32% ) | 124 079 $ | 31/08/2026 |
0,09% | 17/09/2026 | 4 944 ( 0,09% ) | 18 589 $ | 31/08/2026 |
LIPOCINE INC 0,02% | 04/06/2025 | 1 279 ( 0,02% ) | 2 865 $ | 31/08/2026 |
| Sociétés | Poste | Début |
|---|---|---|
Encephalos Life Sciences LLC
Encephalos Life Sciences LLC Miscellaneous Commercial ServicesCommercial Services Operates as a life sciences consulting firm | Fondateur | - |
Bionomics Ltd.
Bionomics Ltd. Pharmaceuticals: GenericHealth Technology Develops drug for treatment of central nervous system disorders | Directeur Général | 05/01/2023 |
| Sociétés | Poste | Fin |
|---|---|---|
| LIPOCINE INC. | Président | 16/04/2026 |
| VIGIL NEUROSCIENCE, INC. | Directeur Technique/Scientifique/R&D | 04/01/2023 |
| ADAMAS PHARMACEUTICALS, INC. | Directeur/Membre du Conseil | 24/11/2021 |
SwanBio Therapeutics, Inc.
SwanBio Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Operates as a clinical stage gene therapy company that develops therapeutics for neurological disorders | Directeur Général | 01/10/2020 |
| ACADIA PHARMACEUTICALS INC. | Corporate Officer/Principal | 01/09/2020 |
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
| Entreprise privées | 10 |
|---|---|
ACADIA Pharmaceuticals, Inc.
ACADIA Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops pharmaceuticals drugs for treatment of central nervous system disorders | Health Technology |
Cavion, Inc.
Cavion, Inc. Pharmaceuticals: MajorHealth Technology Develops and commercializes oncology drugs for solid tumors | Health Technology |
Adamas Pharmaceuticals LLC
Adamas Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Develops, manufactures and markets therapeutics for neurological diseases | Health Technology |
Bionomics Ltd.
Bionomics Ltd. Pharmaceuticals: GenericHealth Technology Develops drug for treatment of central nervous system disorders | Health Technology |
University of Patras
University of Patras Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Semmelweis University
Semmelweis University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Lipocine, Inc.
Lipocine, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company that engages in research and development for the delivery of drugs | Health Technology |
SwanBio Therapeutics, Inc.
SwanBio Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Operates as a clinical stage gene therapy company that develops therapeutics for neurological disorders | Health Technology |
Encephalos Life Sciences LLC
Encephalos Life Sciences LLC Miscellaneous Commercial ServicesCommercial Services Operates as a life sciences consulting firm | Commercial Services |
Vigil Neuroscience, Inc.
Vigil Neuroscience, Inc. BiotechnologyHealth Technology Operates as a clinical-stage biotechnology company that develops therapeutics for neurodegenerative diseases | Health Technology |
Sélectionnez votre édition
Toutes les informations financières adaptées au niveau national